The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: An Italian perspective

Monaldi Archives for Chest Disease

Volumn 51, Issue 4, 1996, Pages 279-288

  Palmer, A J ^a,b   Brandt, A ^a  

^a Inst for Med Info and Biostatist   (Switzerland)

^b IMIB   (Switzerland)

Author keywords

Chemotherapy; Cost effectiveness analysis; Gemcitabine; Meta analysis; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE;

ANEMIA; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; INFECTION; ITALY; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; THROMBOCYTOPENIA; VOMITING;

EID: 0029844206     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Crino L, Scagliotti G, Marangolo M, et al. - Cisplatingemcitabine combination in advanced non-small cell lung cancer (NSCLC): a phase II study. J Clin Oncol 1996 (submitted for publication).
2. Kleisbauer JP, Thomas P, Steward WP, et al. - Combination activity of gemcitabine with cisplatin in non-small cell lung cancer. Gemcitabine: a unique combination of efficacy and tolerability. Lilly Oncology, An Official Satellite of the Fifth International Congress on Anticancer Chemotherapy (ICACC). Abstracts from Paris Conference, 1st February 1995; pp. 10-12.
3. Steward WP, Dunlop DJ, Cameron C, et al. - Gemcitabine and monthly cisplatin in NSCLC. Gemcitabine briefing. Lilly Oncology, Issue One, 1994; pp. 16-17.
4. WHO Handbook for reporting results of cancer treatment. Geneva, WHO Offset Publications, 1979; No. 485.
5. Eddy D, Hasselblad V. - Fast*Pro Software for Metaanalysis by the Confidence Profile Method. San Diego, Academic Press, 1992; pp. 46-47 and 110-111.
6. Advanced version DPL: decision analysis software for Microsoft Windows, ADA. Belmont, Wadsworth Publishing Co., 1995.
7. Ministero della Sanità. Decreto Ministeriale, 14 Dicembre 1994: Tariffe delle Prestazioni di Assistenza Ospedaliera. Gazzetta Ufficiale No. 169 del 24 dicembre, 1994.
8. L'Informatore Farmaceutico, Italian Directory of Medicine and Manufacturers, OEMF, S.G.A., 1995.
9. Crino L, Clerici M, Figoli F, et al. - Chemotherapy of advanced non-small cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1995; 6: 347-353.
10. Depierre A, Chastang Cl, Quoix E, et al. - Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994; 5: 37-42.
11. Klastersky J, Sculier JP, Bureau G, et al. - Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7: 1087-1092.
12. Klastersky J, Sculier JP, Lacroix H, et al. - A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556-1562.
13. Chevalier T, Pujol JL, Douillard JY, et al. - A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of NSCLC: an expanded analysis. Semin Oncol 1994; 21(5) Suppl. 10.
14. Chevalier T, Brisgand D, Douillard JY, et al. - Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced NSCLC: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
15. Baron MG, Artal A, Garrido P, et al. - Randomized phase II trial comparing two chemotherapy combinations for NSCLC. Am J Clin Oncol 1993; 16 (4): 310-314.
16. Baron MG, Feliu J, Espinosa E, et al. - Comparison of two chemotherapeutic regimens - mitomycin + vindesine + cisplatin (MVP) vs mitomycin + ifosfamide + cisplatin (MIP) - in advanced NSCLC. Ann Oncol 1994; 5: 323-327.
17. Berthaud P, Chevalier T, Ruffie P, et al. - Phase I-II study of Navelbine (vinorelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992; 18A: 1863-1865.
18. Cullen MH. - Mitomycin, ifosfamide and cisplatin in NSCLC. Oncology 1993; 50 (Suppl. 1): 31-34.
19. Gatzemeier U, Heckmayr M, Hossfeld DK, Kaukel E, Koschel G, Neuhauss R. - A randomized trial with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide in advanced non-small cell lung cancer. Am J Clin Oncol 1991; 14: 405-411.
20. Giron CG, Ordonez A, Jalon JI, Baron MG. - Combination chemotherapy with ifosfamide, mitomycin and cisplatin in advanced non-small cell lung cancer. Cancer Treat Rep 1987; 71(9): 851.
21. Hainsworth JD, Johnson DH, Hande KR, Greco FA. - Chemotherapy of advanced non-small cell lung cancer: a randomized trial of three cisplatin-based chemotherapy regimens. Am J Clin.Oncol 1989; 12: 345-349.
22. Kaasa S, Lund E, Thorud E, Hatlevojl R, Host H. - Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 1991; 67: 2443-2447.
23. Klastersky J, Sculier JP, Ravez P, et al. - A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 1986; 4: 1780-1786.
24. Paccagnella A, Favaretto A, Brandes A, et al. - Cisplatin, etoposide and ifosfamide in non-small cell lung carcinoma: a phase II randomized study with cisplatin and etoposide as the control arm. Cancer 1990; 65: 2631-2634.
25. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. - A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4: 14-22.
26. Saito H, Shimokata K, Yamamoto M, Saka H, Sakai S, Saito H. - Phase II study of a 72 h concurrent continuous infusion of cisplatin and etoposide in advanced NSCLC. Cancer Chemother Pharmacol 1993; 32: 134-136.
27. Schiller JH, Storer B, Dreicer R, Rosenquist D, Frontiera M, Carbone PP. - Randomized phase II-III trial of combination beta and gamma-interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung. J Natl Cancer Inst 1989; 81: 1739-1743.
28. Garattini L, Grilli R, Scopelliti D, Mantovani L. - A Proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995; 7(1): 1-6.